0957 GMT - Novo Nordisk's new guidance implies a 2% sales and 3% EBIT cut to consensus, UBS analyst Matthew Weston writes. However, the focus of the guidance cut will be the implication for growth heading into 2026, he says. The third-quarter headline miss appears relatively modest at first glance, with sales 2% below and EBIT 4% below expectations, he adds. "While expectations were low going into today's results, we expect continued disappointment on the magnitude of the guidance cut, implications for 2026 growth and the ongoing readacross from Novo's unsolicited offer for Metsera." Shares rise 1.4%. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

November 05, 2025 04:59 ET (09:59 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.